Vascular grafts serve as artificial conduits to replace or bypass diseased arteries, a critical intervention for cardiovascular diseases that remain the leading cause of death globally. For decades, surgeons have relied on synthetic polymers like expanded polytetrafluoroethylene and Dacron, as well as permanent metal stents, but these materials carry inherent limitations: they can provoke chronic inflammation, fail to remodel with growing tissues, and require lifelong anticoagulation or eventual revision. The emergence of biodegradable metallic materials—alloys designed to corrode safely within the body—offers a paradigm shift. These materials provide temporary mechanical support while the natural vessel heals, then gradually dissolve, leaving behind only healthy tissue. This article explores the science behind biodegradable metals, their advantages, remaining challenges, and the latest developments that are steering them toward clinical reality.

Understanding Biodegradable Metallic Materials

Biodegradable metals are engineered to degrade in a controlled manner through corrosion once implanted. The ideal material supports vascular healing for a few months, then completely resorbs without toxic by-products. Three primary families of alloys have emerged: magnesium (Mg)-based, iron (Fe)-based, and zinc (Zn)-based systems. Each offers a unique balance of mechanical strength, degradation rate, and biocompatibility.

Magnesium-Based Alloys

Magnesium is a lightweight metal with a density close to natural bone and excellent biocompatibility—magnesium ions are essential cofactors in over 300 enzymatic reactions. Early Mg alloys, however, corroded too rapidly, releasing hydrogen gas that could form subcutaneous pockets and impair healing. Modern formulations—such as WE43 (Mg-Y-REE) and Mg-Ca alloys—incorporate rare-earth elements or calcium to slow corrosion. Animal studies show these grafts maintain patency for 3–6 months before resorbing, with intimal hyperplasia reduced compared to permanent stents. Researchers continue to refine surface coatings (e.g., fluoridated hydroxyapatite) to fine-tune degradation kinetics.

Iron-Based Alloys

Iron provides superior mechanical strength—important for load-bearing vascular applications—but degrades much more slowly than magnesium. Pure iron remains in the body for years, defeating the purpose of biodegradability. To accelerate corrosion, scientists alloy iron with manganese (Mn), palladium (Pd), or carbon (C). Fe-Mn alloys show promise: they corrode at a rate suitable for large-diameter grafts and exhibit ferromagnetic properties that could aid in imaging. A key advantage is that the degradation products—iron oxides and hydroxides—are readily absorbed into the iron pool and excreted via the reticuloendothelial system, though long-term accumulation risks remain under investigation.

Zinc-Based Alloys

Zinc has emerged as a middle ground between the fast corrosion of Mg and the slow degradation of Fe. Zinc alloys degrade at approximately 0.02 mm per year—ideal for scaffolds that need to remain intact for 6–12 months. Moreover, zinc ions possess antibacterial properties and stimulate endothelial cell proliferation, potentially improving graft healing. Zn-Mg and Zn-Cu alloys are being tested; early rabbit models show complete endothelialization with minimal neointimal thickening. However, zinc’s low mechanical strength compared to magnesium or iron limits its use to smaller-diameter or low-stress applications.

Advantages of Biodegradable Metals in Vascular Grafts

The shift from permanent to temporary support offers multiple clinical benefits, each rooted in the material’s interaction with biological tissues.

Enhanced Biocompatibility and Reduced Inflammation

Unlike permanent metals that can cause chronic foreign-body responses, biodegradable alloys are designed to be actively tolerated. Magnesium, iron, and zinc all participate in essential metabolic pathways. Corrosion products—such as Mg2+, Fe2+, and Zn2+—are naturally occurring ions that cells can process without triggering severe inflammation. Clinical trials of Mg-based coronary stents show lower rates of late lumen loss compared to permanent drug-eluting stents, partly because the degrading surface does not act as a persistent irritant. The controlled release of ions can even modulate macrophage polarization toward a pro-regenerative (M2) phenotype, further reducing inflammation.

Elimination of Long-Term Implant Risks

Permanent implants carry lifelong risks: thrombosis, infection, stent fracture, and the need for antiplatelet regimens. Biodegradable grafts, by disappearing, remove these concerns. Patients may eventually discontinue dual antiplatelet therapy, reducing bleeding risks. The absence of a permanent foreign body also means no late catch-up restenosis—a phenomenon where neoatherosclerosis develops inside stents years after implantation. For pediatric patients with congenital heart defects, biodegradable grafts are especially valuable because they can be designed to degrade as the child grows, eliminating the need for multiple revision surgeries.

Mechanical Support During Tissue Remodeling

Healing of a vascular graft requires a balance: the scaffold must be strong enough to maintain patency and resist collapse, yet flexible enough to accommodate pulsatile flow. Biodegradable metals offer a unique “load-transfer” function. Initially, the alloy carries the mechanical load, allowing the natural vessel to regenerate extracellular matrix. Over weeks to months, as the material corrodes, mechanical stresses gradually shift to the newly formed tissue. This dynamic loading guides collagen alignment and smooth muscle cell orientation, resulting in a vessel with mechanical properties close to native artery. Studies with Mg-RE alloy grafts in porcine iliac arteries demonstrate improved viscoelasticity compared to both synthetic grafts and bare native vessels after 6 months.

Promotion of Tissue Integration and Healing

The degradation by-products of biodegradable metals are not inert; they actively influence cellular behavior. Magnesium ions stimulate angiogenesis and upregulate vascular endothelial growth factor (VEGF). Zinc ions promote endothelial proliferation and migration while inhibiting smooth muscle cell hyperplasia in a concentration-dependent manner. Iron degradation products, in small quantities, can enhance mitochondrial function in endothelial cells. This biological activity can accelerate endothelialization—the formation of a new intimal lining—which is critical for preventing thrombosis. Preclinical studies of Zn-Mg grafts report complete luminal coverage by endothelial cells within 4 weeks, far faster than with conventional ePTFE grafts.

Key Challenges and Engineering Solutions

Despite their promise, biodegradable metallic grafts are not yet ready for widespread clinical use. Three major hurdles—degradation rate control, mechanical integrity over time, and biocompatibility of corrosion products—require sophisticated engineering approaches.

Controlling Degradation Rate

The ideal degradation profile should match the tissue healing timeline: rapid enough to avoid chronic foreign-body presence, yet slow enough to maintain structural support for 3–6 months in large arteries and up to 12 months in small-diameter grafts. Achieving this is difficult because corrosion rates depend on local pH, flow-induced shear stress, and protein adsorption—all variables that differ between patients and vessel locations. Researchers employ alloying (e.g., adding Ca or Sr to Mg), grain refinement through severe plastic deformation, and protective coatings. Poly-lactic acid (PLA) and calcium phosphate coatings can delay corrosion onset by several weeks. Advanced techniques like anodization produce a thick, porous oxide layer that slows degradation while promoting bone-like apatite formation for better tissue binding. Recent work demonstrates that a micro-arc oxidation coating on Mg-Zn-Ca alloy reduces in vivo degradation by 40% without compromising biocompatibility.

Maintaining Mechanical Integrity During Degradation

As the material corrodes, its cross-section reduces, potentially leading to premature fracture or collapse. Engineers must design grafts with a safety margin that accounts for this loss. Finite element models that simulate progressive corrosion under cyclic loading inform optimal strut dimensions and alloy composition. Hybrid designs—metal scaffold embedded in a bioresorbable polymer matrix—can provide redundancy: the polymer supports the vessel after the metal has largely degraded. Another strategy is to use iron alloys with very slow corrosion rates for the load-bearing phase, with a thin magnesium coating that dissolves first, leaving a smooth interface. The challenge is to ensure that the degradation front remains uniform; localized pitting can create stress risers and rapid failure. Improving corrosion uniformity through heat treatment and inclusion refinement is an active area of research.

Toxicity of Degradation By-products

While magnesium, iron, and zinc ions are essential nutrients, excessive local concentrations can be cytotoxic. Magnesium ions above 10 mM impair cell proliferation; free iron can catalyze oxidative stress; high zinc levels interfere with copper metabolism. The body’s homeostatic mechanisms handle small amounts, but a degrading graft releases ions in bursts. Animal studies show that Mg-based grafts produce only transient elevations in serum Mg, quickly cleared by kidneys. For iron, macrophages in the liver and spleen efficiently sequester iron oxide particles, but long-term accumulation could worsen conditions like hemochromatosis. To mitigate toxicity, researchers are developing alloys that release multiple ions in a synergistic balance—for example, Zn-Mg-Ca alloys where calcium helps buffer pH changes and zinc’s antibacterial action reduces infection risk, allowing lower metal concentrations overall. Surface modifications that trap corrosion products locally, releasing them in a controlled, sustained manner, are under active investigation.

Recent Research and Preclinical Applications

The pipeline of biodegradable metallic vascular grafts is advancing rapidly, with several promising studies reporting successes in large animal models over the past five years.

Magnesium-Based Grafts in Porcine Models

A landmark study published in Acta Biomaterialia (2022) evaluated a WE43 magnesium alloy scaffold in the iliac arteries of minipigs. The grafts were coated with a thin polycaprolactone (PCL) layer to slow initial corrosion. Angiography and optical coherence tomography at 12 months showed 92% patency, with complete degradation of the metallic scaffold by month 18. Histology revealed a well-organized neointima with layered smooth muscle cells and a confluent endothelial monolayer. Importantly, no aneurysmal dilation or late stent thrombosis occurred. These results indicate that Mg-based grafts can safely support vascular remodeling and then disappear without adverse sequelae. The study’s lead author noted that the combination of coating technology and optimized alloy composition was key to matching degradation to porcine healing rates, which are approximately 1.5 times faster than human healing.

Zinc Alloy Grafts for Small-Diameter Arteries

Small-diameter grafts (less than 6 mm) remain the most challenging clinical need because synthetic materials fail due to thrombosis and intimal hyperplasia. Zinc alloys, with their moderate corrosion rate and bioactive ion release, are particularly attractive for this application. Researchers at Helmholtz-Zentrum Geesthacht implanted Zn-0.8Mg and Zn-1.5Mg alloy grafts in the carotid arteries of rabbits. After 6 months, all grafts were patent with a uniform, thin neointima. Scanning electron microscopy showed a complete endothelial cover. The degradation layer was only 50–80 µm thick, and the remaining metal retained sufficient strength. Plasma zinc levels remained within normal range. This work suggests zinc alloys could fill the gap for coronary and peripheral bypass grafts where autologous veins are unavailable.

Iron-Manganese Scaffolds for Large Vessels

For large-diameter applications such as aortic aneurysms, mechanical strength is paramount. Iron-based scaffolds offer the highest radial strength among biodegradable metals. In a sheep model of descending aortic replacement, Fe-30Mn alloy grafts showed excellent resistance to pulsatile pressure, with only 5% diameter change under systolic loading. Corrosion was uniform and slow—only 15% mass loss after 12 months—with a protective corrosion layer forming after initial rapid corrosion. The neotissue that formed on the luminal surface was indistinguishable from native aortic tissue after 18 months. However, complete resorption will take more than 2 years, raising concerns about long-term iron accumulation. Ongoing studies are exploring the addition of Mn to increase corrosion rate and the use of iron-zinc composites to accelerate dissolution while maintaining strength.

Future Directions and Clinical Translation

The journey from bench to bedside for biodegradable metallic grafts will require solving several remaining puzzles: scaling up manufacturing to produce consistent, sterile grafts with precise degradation profiles; conducting long-term animal studies that mimic human metabolism (especially for iron); and designing clinical trials that can demonstrate superiority over current gold standards. Personalized grafts, where the degradation rate is tuned to a patient’s age, disease state, and healing capacity, could become possible using additive manufacturing (3D printing) of biodegradable metal powders. Combining drug elution (e.g., sirolimus or everolimus) with biodegradable metal scaffolds may further reduce neointimal hyperplasia. The first human clinical trials for magnesium-based coronary stents (e.g., the BIOSOLVE series) have already shown safety and efficacy, and several ongoing studies are extending this concept to peripheral arteries. With continued innovation in alloy design and surface engineering, biodegradable metallic vascular grafts are poised to become the standard of care within the next decade—transforming cardiovascular surgery by reducing permanent implants, eliminating revision surgeries, and harnessing the body’s own healing capacity.